CEO: Jon Moore

Advent Contact: Raj Parekh & Jon Moore

Developing remyelinating and neuroprotective therapies for Multiple Sclerosis.

Pheno Therapeutics aims to identify novel remyelinating agents and develop transformational therapeutics that enhance the repair of damaged myelin sheaths in Multiple Sclerosis patients. The company was founded by Advent Life Sciences and the University of Edinburgh to build on the ground breaking research of Prof Siddharthan Chandran and Prof Neil Carragher, world class experts in multiple sclerosis and stem cell biology, and phenotypic screening, respectively.

Advent founded Pheno Therapeutics in 2019.

New company takes aim at treatments for multiple sclerosis